Hydroxyurea

Research use only, not for human use.

Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.(In Vitro):Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The Gγ: Aγ-globin mRNA is induced 0.30- to 8-fold in vitro. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages.(In Vivo):Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice.

——

——

NCI C04831 | NSC 32065

Cell Cycle/DNA Damage

DNA/RNA Synthesis

ribonucleoside diphosphate reductase

Cancer

——

127-07-1

76.06

CH4N2O2

>98% (HPLC)

Water: 15 mg/mL (197.23 mM); DMSO: 15 mg/mL (197.23 mM)

O=C(N)NO

1-hydroxyurea

(-20℃)

With Ice Pack

≥ 2 years